Sorry!! The article you are trying to read is not available now.
Abbott Laboratories (NY: ABT)
38.93 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(ABT) Community Analysis from
April 21, 2014
(Jutia Group, 3/28/14)
[PR Newswire] - ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ -- Abbott today announced that its Supera®...(read more)
(Jutia Group, 2/5/14)
[at Bloomberg] - Abbott Laboratories (ABT) and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug...(read more)
(Stock Blog Hub, 8/21/13)
Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting...(read more)
Abbott Laboratories (ABT) Company Overview

Abbott Laboratories (NYSE: ABT) is the largest company in the nutritional products market and the second largest company in the worldwide market for diagnostic products. The company manufactures a number of nutritional and pharmaceutical products, laboratory diagnostics, pharmaceutical therapies and medical devices, including the arthritis medication Humira and the coronary stent Xience. In FY 2010, Abbott generated revenues of $35.17B and net earnings of $4.6B.[1]

Abbott and the rest of the pharmaceutical industry are continually under pressure from expiring patents. Patent expiration allows generic drug companies to lower prices for a certain medication by producing their own versions, increasing competition for that product's market.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE